Geode Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $170M | Buy |
1,533,698
+117,429
| +8% | +$10.6M | 0.01% | 898 |
|
|
2026
Q1 | $123M | Buy |
1,416,269
+40,540
| +3% | +$3.94M | 0.01% | 960 |
|
|
2025
Q4 | $147M | Buy |
1,375,729
+12,900
| +0.9% | +$1.37M | 0.01% | 860 |
|
|
2025
Q3 | $138M | Buy |
1,362,829
+51,576
| +4% | +$4.79M | 0.01% | 884 |
|
|
2025
Q2 | $82.9M | Buy |
1,311,253
+24,085
| +2% | +$1.47M | 0.01% | 1138 |
|
|
2025
Q1 | $68.2M | Buy |
1,287,168
+31,369
| +2% | +$1.74M | 0.01% | 1192 |
|
|
2024
Q4 | $70.3M | Sell |
1,255,799
-389
| -0% | -$21.5K | 0.01% | 1212 |
|
|
2024
Q3 | $65.8M | Buy |
1,256,188
+3,499
| +0.3% | +$168K | 0.01% | 1260 |
|
|
2024
Q2 | $51.4M | Buy |
1,252,689
+71,984
| +6% | +$2.87M | ﹤0.01% | 1345 |
|
|
2024
Q1 | $51.2M | Buy |
1,180,705
+61,576
| +6% | +$2.69M | ﹤0.01% | 1336 |
|
|
2023
Q4 | $51.5M | Buy |
1,119,129
+74,072
| +7% | +$2.34M | 0.01% | 1332 |
|
|
2023
Q3 | $24M | Buy |
1,045,057
+71,707
| +7% | +$1.61M | ﹤0.01% | 1710 |
|
|
2023
Q2 | $16.1M | Buy |
973,350
+500,589
| +106% | +$9.04M | ﹤0.01% | 2003 |
|
|
2023
Q1 | $8.43M | Buy |
472,761
+14,251
| +3% | +$358K | ﹤0.01% | 2364 |
|
|
2022
Q4 | $13.4M | Buy |
458,510
+70,398
| +18% | +$1.81M | ﹤0.01% | 2058 |
|
|
2022
Q3 | $9.51M | Sell |
388,112
-11,682
| -3% | -$217K | ﹤0.01% | 2299 |
|
|
2022
Q2 | $1.66M | Sell |
399,794
-341,095
| -46% | -$1.87M | ﹤0.01% | 3185 |
|
|
2022
Q1 | $8.54M | Buy |
740,889
+26,861
| +4% | +$236K | ﹤0.01% | 2458 |
|
|
2021
Q4 | $7.13M | Buy |
714,028
+46,370
| +7% | +$521K | ﹤0.01% | 2676 |
|
|
2021
Q3 | $8.72M | Sell |
667,658
-17,245
| -3% | -$263K | ﹤0.01% | 2552 |
|
|
2021
Q2 | $13.4M | Buy |
684,903
+61,341
| +10% | +$1.27M | ﹤0.01% | 2256 |
|
|
2021
Q1 | $13.3M | Buy |
623,562
+135,115
| +28% | +$3.92M | ﹤0.01% | 2156 |
|
|
2020
Q4 | $14.5M | Sell |
488,447
-3,232
| -0.7% | -$82.1K | ﹤0.01% | 1912 |
|
|
2020
Q3 | $10.7M | Buy |
491,679
+14,929
| +3% | +$342K | ﹤0.01% | 1899 |
|
|
2020
Q2 | $10.6M | Buy |
476,750
+33,493
| +8% | +$653K | ﹤0.01% | 1897 |
|
|
2020
Q1 | $6.75M | Buy |
443,257
+45,382
| +11% | +$813K | ﹤0.01% | 1971 |
|
|
2019
Q4 | $9.13M | Buy |
397,875
+80,602
| +25% | +$1.79M | ﹤0.01% | 2077 |
|
|
2019
Q3 | $6.85M | Buy |
317,273
+4,737
| +2% | +$102K | ﹤0.01% | 2193 |
|
|
2019
Q2 | $6.88M | Buy |
312,536
+60,519
| +24% | +$1.53M | ﹤0.01% | 2186 |
|
|
2019
Q1 | $6.91M | Buy |
252,017
+18,123
| +8% | +$521K | ﹤0.01% | 2133 |
|
|
2018
Q4 | $6.29M | Buy |
233,894
+54,247
| +30% | +$1.5M | ﹤0.01% | 2075 |
|
|
2018
Q3 | $5.24M | Buy |
179,647
+88,819
| +98% | +$2.81M | ﹤0.01% | 2330 |
|
|
2018
Q2 | $2.84M | Sell |
90,828
-28,530
| -24% | -$780K | ﹤0.01% | 2656 |
|
|
2018
Q1 | $2.38M | Sell |
119,358
-4,437
| -4% | -$118K | ﹤0.01% | 2671 |
|
|
2017
Q4 | $3.6M | Buy |
+123,795
| New | +$3.27M | ﹤0.01% | 2412 |
|
Other funds holding RYTM
RCM
BBA
PA
Geode Capital Management's RYTM Position: Q2 2026 in Review
Geode Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 8.3% in Q2 2026, buying an estimated $10.6M and bringing the position to 1,533,698 shares worth $170M. The position accounts for 0.01% of the portfolio, ranked #898.
Geode Capital Management first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.
- Geode Capital Management held 1,533,698 shares of Rhythm Pharmaceuticals worth $170M as of Q2 2026.
- Geode Capital Management bought 117,429 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $10.6M.
- Rhythm Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #898 holding.
- Geode Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.